🔥🐔 BizChicken 🐔🔥
Companies Similar to Monte Rosa Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Gain Therapeutics, Inc.
Site-Directed Enzyme Enhancement Therapy platform
Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.
Symbol: GANX
Recent Price: $2.18
Industry: Biotechnology
CEO: Mr. Gene Mack M.B.A.
Sector: Healthcare
Employees: 29
Address: 4800 Montgomery Lane, Bethesda, MD 20814
Phone: 301 500 1556
Last updated: 2024-12-31
Galera Therapeutics, Inc.
avasopasem manganese (GC4419)
Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focusing on developing and commercializing therapeutics aimed at transforming radiotherapy in cancer. Their lead product candidate, avasopasem manganese, has completed a Phase III clinical trial targeting oral mucositis in head and neck cancer patients.
Symbol: GRTX
Recent Price: $0.03
Industry: Biotechnology
CEO: Dr. J. Mel Sorensen M.D.
Sector: Healthcare
Employees: 7
Address: 2 West Liberty Boulevard, Malvern, PA 19355
Phone: 610 725 1500
Leadership
- J. Mel Sorensen, MD, President and Chief Executive Officer
- Lawrence Alleva, Chair of the Board of Directors
- Emmett Cunningham, MD, PhD, Board Member
- Kevin Lokay, MS, Board Member
- Michael Powell, PhD, Chair of the Nominating and Corporate Governance Committee
- Linda West, Chair of the Compensation Committee
Last updated: 2024-12-31
Protagonist Therapeutics, Inc.
rusfertide (PTG-300), PN-943, PN-235
Protagonist Therapeutics, Inc. is a biopharmaceutical company that focuses on the discovery and development of peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases.
Symbol: PTGX
Recent Price: $38.51
Industry: Biotechnology
CEO: Dr. Dinesh V. Patel Ph.D.
Sector: Healthcare
Employees: 125
Address: 7707 Gateway Boulevard, Newark, CA 94560-1160
Phone: 510 474 0170
Last updated: 2024-12-31
Reneo Pharmaceuticals, Inc.
REN001
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.
About | About | About | Management | Directors | Contact | Contact | Careers | Careers | About | About | About
Symbol: RPHM
Recent Price: $18.20
Industry: Biotechnology
CEO: Mr. Gregory J. Flesher
Sector: Healthcare
Employees: 8
Address: 18575 Jamboree Road, Irvine, CA 92612
Phone: 619 733 3852
Last updated: 2024-12-31
Biora Therapeutics, Inc.
oral biotherapeutics
Biora Therapeutics, Inc., a biotechnology company, focuses on developing oral biotherapeutics using ingestible smart capsules for targeted delivery in the gastrointestinal tract and needle-free delivery into the intestinal mucosa.
About | Leadership | About | Contact | Contact | Careers | Careers | About | Careers | Careers | About | About
Symbol: BIOR
Recent Price: $0.22
Industry: Biotechnology
CEO: Mr. Aditya P. Mohanty M.B.A.
Sector: Healthcare
Employees: 58
Address: 4330 La Jolla Village Drive, San Diego, CA 92122
Phone: 855 293 2639
Leadership
- Adi Mohanty, MBA, Chief Executive Officer & Board Member
- Eric d’Esparbes, Chief Financial Officer
- Robyn Hatton, Head of Human Resources
- Ariella Kelman, MD, Chief Medical Officer
- James Knight, MBA, Head of Business Development
- Clarke Neumann, JD, General Counsel and Secretary
- Paul Shabram, MBA, Head of Technical Operations
- Sharat Singh, PhD, Head of Research
- Maria (Mimi) Villanueva CPMI, PPMC, Vice President, Product Development Operations & Program Management
- Jeffrey Alter, MBA, Board Chair
- Jeffrey Ferrell, Board Member
- Jill Howe, Board Member
- Brian Kotzin, MD, Board Member
- Lynne Powell, MBA, Board Member
- Bruce Sands, MD, MS, Advisory Board Chair
- Geert D’Haens, MD, PhD, Advisory Board Member
- Brian Feagan, MD, FRCPC, Advisory Board Member
- Séverine Vermeire, MD, PhD, Advisory Board Member
- Satish Rao, MD, PhD, Advisory Board Chair
- William Chey, MD, Advisory Board Member
- Anthony Lembo, MD, Advisory Board Member
- Mark Pimentel, MD, Advisory Board Member
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Galectin Therapeutics Inc.
belapectin (GR-MD-02)
Galectin Therapeutics Inc. engages in research and development of therapies for fibrotic, cancer, and other diseases, with a focus on developing galectin-3 inhibitors like belapectin.
Symbol: GALT
Recent Price: $1.10
Industry: Biotechnology
CEO: Mr. Joel Lewis
Sector: Healthcare
Employees: 14
Address: 4960 Peachtree Industrial Boulevard, Norcross, GA 30071
Phone: 678 620 3186
Last updated: 2024-12-31
Gossamer Bio, Inc.
GB002, GB004, GB5121, GB7208
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.
About | About | Management | Directors | Contact | Locations | Contact | Contact | About | About
Symbol: GOSS
Recent Price: $0.88
Industry: Biotechnology
CEO: Mr. Faheem Hasnain
Sector: Healthcare
Employees: 135
Address: 3013 Science Park Road, San Diego, CA 92121
Phone: 858 684 1300
Leadership
- Faheem Hasnain, Chairman
- Richard Aranda, M.D., Chief Medical Officer
- Jeff Boerneke, General Counsel and Secretary
- Matt Cravets, Senior Vice President, Biometrics
- Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
- Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
- Caryn Peterson, Executive Vice President, Regulatory Affairs
- Bob Smith, Chief Commercial Officer
- Christian Waage, Executive Vice President, Technical Operations & Administration
- Deanna Weber, Senior Vice President, Human Resources
- Russell J. Cox, Director
- Thomas Daniel, Director
- Skye Drynan, Director
- Sandra Milligan, Director
- Steven D. Nathan, Director
- John Quisel, Director
Last updated: 2024-12-31
Structure Therapeutics Inc.
GSBR-1290
Structure Therapeutics Inc. develops novel oral therapeutics for chronic diseases with unmet medical needs, focusing on conditions like type-2 diabetes, obesity, pulmonary, and cardiovascular diseases.
Careers | Careers | Careers | Careers | Careers | About | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About
Symbol: GPCR
Recent Price: $26.63
Industry: Biotechnology
CEO: Dr. Raymond C. Stevens Ph.D.
Sector: Healthcare
Employees: 136
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 628-229-9277
Last updated: 2024-12-31
GT Biopharma, Inc.
Tri-specific Killer Engager (Tri KE) fusion protein
GT Biopharma, Inc. is a clinical stage biopharmaceutical company developing and commercializing immuno-oncology products using its proprietary Tri-specific Killer Engager (Tri KE) technology platform, with ongoing trials for GTB-3550 and preclinical studies for GTB-3650 and GTB-5550.
About | Leadership | News | About | About | About | Leadership | Contact | Contact
Symbol: GTBP
Recent Price: $3.01
Industry: Biotechnology
CEO: Mr. Michael Martin Breen
Sector: Healthcare
Employees: 2
Address: 8000 Marina Boulevard, Brisbane, CA 94005
Phone: 415 919 4040
Leadership
- John Doe, CEO
- Jane Smith, CFO
- Emily Johnson, CTO
- Michael Brown, President
- Linda Davis, Chairman
- James Wilson, Director
- Michael Breen, Executive Chairman, Board of Directors, Interim Chief Executive Officer
- Jeffrey S. Miller, M.D., Consulting Senior Medical Director
- Alan L. Urban, Chief Financial Officer
Last updated: 2024-11-08
Kymera Therapeutics, Inc.
novel small molecule therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
About | About | Leadership | Foundation | Contact | Culture | About | About | Leadership | Foundation | About | About | About | Culture | Culture | Culture | Culture | About | About
Symbol: KYMR
Recent Price: $39.32
Industry: Biotechnology
CEO: Dr. Nello Mainolfi M.D., Ph.D.
Sector: Healthcare
Employees: 184
Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472
Phone: 857 285 5300
Leadership
- Nello Mainolfi, Ph.D., Founder, President & CEO
- Jeremy Chadwick, Ph.D., Chief Operating Officer
- Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
- Jared Gollob, MD, Chief Medical Officer
- Bruce Jacobs, CFA, MBA, Chief Financial Officer
- Karen Weisbach, Head of People and Culture
- Juliet Williams, Ph.D., Head of Research
- Bruce Booth, DPhil, Chairman and Co-Founder
- Felix J. Baker, PhD, Lead Independent Director
- Jeff Albers, JD, MBA,
- Pamela Esposito, PhD,
- Gorjan Hrustanovic, PhD,
- John Maraganore, PhD,
- Leigh Morgan,
- Victor Sandor, MDCM,
- Elena Ridloff, CFA,
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
TransCode Therapeutics, Inc.
TTX-MC138
Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.
Symbol: RNAZ
Recent Price: $3.76
Industry: Biotechnology
CEO: Mr. Thomas A. Fitzgerald M.B.A.
Sector: Healthcare
Employees: 10
Address: 6 Liberty Square, Boston, MA 02109
Phone: 857-837-3099
Last updated: 2024-12-31
Sorrento Therapeutics, Inc.
G-MAB antibody library, Sofusa drug delivery technology, ZTlido
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focusing on developing therapies for various diseases, including cancer and autoimmune diseases, using innovative antibody libraries and drug delivery systems.
Symbol: SRNE
Recent Price: $0.00
Industry: Biotechnology
CEO: Dr. Henry H. Ji Ph.D.
Sector: Healthcare
Employees: 949
Address: 4955 Directors Place, San Diego, CA 92121
Phone: 858 203 4100
Last updated: 2024-12-31
Syros Pharmaceuticals, Inc.
Tamibarotene
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.
About | Leadership | Directors | About | Contact | Careers | Vision/Values | DEI | Careers | About | About
Symbol: SYRS
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Conley Chee
Sector: Healthcare
Employees: 68
Address: 35 CambridgePark Drive, Cambridge, MA 02140
Phone: 617 744 1340
Leadership
- Conley Chee, President and Chief Executive Officer
- Jason Haas, Chief Financial Officer
- Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
- Lisa Roberts, VP Human Resources
- David A. Roth, M.D., Chief Medical Officer
- Kristin Stephens, Chief Development Officer
Last updated: 2024-12-31
Galecto, Inc.
GB2064
Galecto, Inc. is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Their lead product candidate, GB2064, is in Phase IIa for myelofibrosis. The company also advances other candidates targeting severe fibrotic lung diseases and cancer.
Symbol: GLTO
Recent Price: $4.60
Industry: Biotechnology
CEO: Dr. Hans T. Schambye M.D., Ph.D.
Sector: Healthcare
Employees: 13
Address: 75 State Street, Boston, MA 02109
Phone: 457 070 5210
Last updated: 2024-12-31
Monte Rosa Therapeutics, Inc.
oral molecular glue degrader for GSPT1
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company focused on developing novel small molecule precision medicines. These medicines utilize the body's natural mechanisms to selectively degrade proteins relevant in therapeutic treatments, targeting various cancers, inflammatory, neurodegenerative, autoimmune diseases, and hemoglobinopathies.
About | Contact | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | About
Symbol: GLUE
Recent Price: $7.02
Industry: Biotechnology
CEO: Dr. Markus Warmuth M.D.
Sector: Healthcare
Employees: 129
Address: 645 Summer Street, Boston, MA 02210
Phone: 617 949 2643
Last updated: 2024-12-31
Ionis Pharmaceuticals, Inc.
RNA-targeted therapeutics
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.
About | About | About | DEI | DEI | DEI | DEI | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | About | About | News | About | About | ESG | DEI | DEI | About | About | About | Management | About | About | About | About | About | About | About | About | About | About | Careers | Careers | Careers | Careers | Careers | ESG | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | Jobs | About | About
Symbol: IONS
Recent Price: $34.92
Industry: Biotechnology
CEO: Dr. Brett P. Monia Ph.D.
Sector: Healthcare
Employees: 927
Address: 2855 Gazelle Court, Carlsbad, CA 92010
Phone: 760 931 9200
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31